Atossa Therapeutics (NASDAQ:ATOS) Price Target Raised to $6.25 at Ascendiant Capital Markets

Atossa Therapeutics (NASDAQ:ATOSFree Report) had its price objective hoisted by Ascendiant Capital Markets from $6.00 to $6.25 in a research report sent to investors on Thursday, Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other brokerages have also commented on ATOS. StockNews.com raised shares of Atossa Therapeutics from a sell rating to a hold rating in a report on Tuesday, May 14th. HC Wainwright increased their price objective on shares of Atossa Therapeutics from $4.00 to $6.00 and gave the stock a buy rating in a report on Monday, May 13th. Finally, Cantor Fitzgerald reissued an overweight rating on shares of Atossa Therapeutics in a report on Tuesday, May 14th.

Get Our Latest Analysis on Atossa Therapeutics

Atossa Therapeutics Stock Performance

ATOS opened at $1.27 on Thursday. The firm’s 50-day simple moving average is $1.58 and its 200-day simple moving average is $1.18. Atossa Therapeutics has a twelve month low of $0.62 and a twelve month high of $2.31. The firm has a market cap of $159.71 million, a price-to-earnings ratio of -5.29 and a beta of 1.19.

Atossa Therapeutics (NASDAQ:ATOSGet Free Report) last posted its earnings results on Monday, May 13th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.02. As a group, sell-side analysts anticipate that Atossa Therapeutics will post -0.23 EPS for the current fiscal year.

Insider Transactions at Atossa Therapeutics

In other Atossa Therapeutics news, Director Jonathan Finn purchased 25,000 shares of the stock in a transaction dated Wednesday, April 10th. The stock was bought at an average price of $1.77 per share, for a total transaction of $44,250.00. Following the transaction, the director now directly owns 25,000 shares in the company, valued at $44,250. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 7.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Atossa Therapeutics

Several institutional investors have recently modified their holdings of ATOS. PFG Investments LLC bought a new position in Atossa Therapeutics during the 1st quarter worth approximately $43,000. Cetera Advisors LLC bought a new position in Atossa Therapeutics during the 1st quarter worth approximately $72,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in Atossa Therapeutics during the 3rd quarter worth approximately $98,000. Virtu Financial LLC bought a new position in Atossa Therapeutics during the 1st quarter worth approximately $151,000. Finally, Vanguard Group Inc. boosted its stake in Atossa Therapeutics by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock worth $10,357,000 after acquiring an additional 78,269 shares during the last quarter. Institutional investors and hedge funds own 12.74% of the company’s stock.

About Atossa Therapeutics

(Get Free Report)

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

Further Reading

Receive News & Ratings for Atossa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.